Market Cap 3.05M
Revenue (ttm) 0.00
Net Income (ttm) -13.39M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 144,900
Avg Vol 259,221
Day's Range N/A - N/A
Shares Out 2.59M
Stochastic %K 17%
Beta 1.69
Analysts Hold
Price Target $3.02

Company Profile

Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening viral infectious, diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device intended for applications in cancer, and life-threatening viral infections, and use in organ transplantation. The company was founded in 1984 and is based in San Diego, California.

Industry: Medical Devices
Sector: Healthcare
Phone: 619 941 0360
Fax: 619 941 0361
Address:
11555 Sorrento Valley Road, Suite 203, San Diego, United States
Harley18
Harley18 Jul. 13 at 9:49 PM
$AEMD dam it’s quite
0 · Reply
Quacks206
Quacks206 Jul. 10 at 7:24 PM
$AEMD looks bottomed
0 · Reply
Celz
Celz Jul. 10 at 5:14 PM
$AEMD usual P&D AH/PM scam stock
0 · Reply
UNCLE_SCROOGE_
UNCLE_SCROOGE_ Jul. 10 at 2:12 PM
$AEMD 😂... I'm very happy for this trash...
0 · Reply
marel_corp
marel_corp Jul. 10 at 1:56 PM
$AEMD where is the press release?
1 · Reply
Quacks206
Quacks206 Jul. 10 at 1:41 PM
$AEMD in this one, looks very undervalued and beat up recently. Looks like a good opportunity
0 · Reply
trader2360
trader2360 Jul. 10 at 1:22 PM
$AEMD aemd give me a 2
0 · Reply
lecorb
lecorb Jul. 10 at 1:01 PM
0 · Reply
trader2360
trader2360 Jul. 10 at 12:49 PM
$AEMD, grab it, don't chase it
0 · Reply
YoungMistral
YoungMistral Jul. 10 at 12:22 PM
0 · Reply
Latest News on AEMD
Aethlon Medical, Inc. (AEMD) Q4 2025 Earnings Call Transcript

Jun 26, 2025, 7:35 PM EDT - 17 days ago

Aethlon Medical, Inc. (AEMD) Q4 2025 Earnings Call Transcript


Aethlon Medical, Inc. (AEMD) Q3 2025 Earnings Call Transcript

Feb 12, 2025, 8:11 PM EST - 5 months ago

Aethlon Medical, Inc. (AEMD) Q3 2025 Earnings Call Transcript


Aethlon Medical, Inc. (AEMD) Q2 2025 Earnings Call Transcript

Nov 13, 2024, 7:58 PM EST - 8 months ago

Aethlon Medical, Inc. (AEMD) Q2 2025 Earnings Call Transcript


Immunotherapy Clinical Trials - A New Approach to Treating Cancer

Sep 19, 2024, 10:00 AM EDT - 10 months ago

Immunotherapy Clinical Trials - A New Approach to Treating Cancer


Innovation Driving Cancer's Solid Tumors Market

Sep 17, 2024, 7:30 AM EDT - 10 months ago

Innovation Driving Cancer's Solid Tumors Market


Aethlon Medical, Inc. (AEMD) Q1 2025 Earnings Call Transcript

Aug 14, 2024, 6:45 PM EDT - 11 months ago

Aethlon Medical, Inc. (AEMD) Q1 2025 Earnings Call Transcript


Aethlon Medical, Inc. (AEMD) Q4 2024 Earnings Call Transcript

Jun 27, 2024, 6:37 PM EDT - 1 year ago

Aethlon Medical, Inc. (AEMD) Q4 2024 Earnings Call Transcript


The Hunt for Virus Treatments Continues Post Covid-19

Jun 7, 2024, 8:00 AM EDT - 1 year ago

The Hunt for Virus Treatments Continues Post Covid-19


Aethlon Medical, Inc. (AEMD) Q3 2024 Earnings Call Transcript

Feb 14, 2024, 9:17 PM EST - 1 year ago

Aethlon Medical, Inc. (AEMD) Q3 2024 Earnings Call Transcript


Aethlon Medical, Inc. (AEMD) Q2 2024 Earnings Call Transcript

Nov 14, 2023, 10:01 PM EST - 1 year ago

Aethlon Medical, Inc. (AEMD) Q2 2024 Earnings Call Transcript


Harley18
Harley18 Jul. 13 at 9:49 PM
$AEMD dam it’s quite
0 · Reply
Quacks206
Quacks206 Jul. 10 at 7:24 PM
$AEMD looks bottomed
0 · Reply
Celz
Celz Jul. 10 at 5:14 PM
$AEMD usual P&D AH/PM scam stock
0 · Reply
UNCLE_SCROOGE_
UNCLE_SCROOGE_ Jul. 10 at 2:12 PM
$AEMD 😂... I'm very happy for this trash...
0 · Reply
marel_corp
marel_corp Jul. 10 at 1:56 PM
$AEMD where is the press release?
1 · Reply
Quacks206
Quacks206 Jul. 10 at 1:41 PM
$AEMD in this one, looks very undervalued and beat up recently. Looks like a good opportunity
0 · Reply
trader2360
trader2360 Jul. 10 at 1:22 PM
$AEMD aemd give me a 2
0 · Reply
lecorb
lecorb Jul. 10 at 1:01 PM
0 · Reply
trader2360
trader2360 Jul. 10 at 12:49 PM
$AEMD, grab it, don't chase it
0 · Reply
YoungMistral
YoungMistral Jul. 10 at 12:22 PM
0 · Reply
Harley18
Harley18 Jul. 10 at 12:22 PM
0 · Reply
roadto1k
roadto1k Jul. 10 at 11:43 AM
$AEMD why is this room so quiet?? Also this seems like a good price for entry.
0 · Reply
Firedolphin21
Firedolphin21 Jul. 10 at 10:42 AM
$PHH $HERZ $AEMD $SUGP $PROK DBR .. the best... there is a reason over 32k follow him..
1 · Reply
Tryitin
Tryitin Jul. 10 at 4:25 AM
$CELZ seem to have better chart pattern and gap up overnight than $AEMD Both are patent news stock. Hope we bank tomorrow. Good night!
0 · Reply
JL_TradeZ
JL_TradeZ Jul. 10 at 1:50 AM
💎MAIN WATCHLIST JULY 10th Lining up five clean setups for tomorrow. All of them have real catalysts, micro floats, and are coiling right under the key breakout levels. Volume already came in heavy on most of these, and there’s no live dilution on any of them right now. If the market gives follow-through, these can move fast. — $BMGL coiled under 3.41 after a 98% move today on 85M+ volume. The float is only 5.82M and there’s no offering filed yet, though they did approve a lock-up waiver. The catalyst chain is aggressive: a $1B Bitcoin acquisition plan and a $375M healthcare AI contract. If 3.41 breaks with size, this could run toward 4 fast. $AEMD has insider buys confirmed July 1, strong earnings on June 26, and progress in its Hemopurifier cancer trial. The float is just 2.43M, and there’s no dilution. It’s curling off the bottom with a clean coil around 1.29 and MACD confirming. If 1.33 breaks, this has room toward 1.50+. $ALUR announced a new Canada distribution deal this afternoon, right after its FDA PMA submission and pivotal trial data earlier this week. Volume rotated 25% of the float already and after-hours stayed strong. If this breaks 3.20 tomorrow, the momentum could kick in fast with biotech sector tailwinds. $GLMD is setting up tight under 2.22 with a float under 2.2M, no dilution, and a chart that’s stacked on every timeframe. They recently confirmed Aramchol enhances Bayer’s Regorafenib in cancer models and released a new biomarker signature for expansion beyond NASH. If it breaks 2.22, this can be a clean breakout $BENF is a confirmed float rotation setup that held strong into the close. SEC investigation officially closed July 2, a $1.91M capital transaction was filed June 24, and they resolved the GWG case June 17. The chart is coiled under 0.346, and if that breaks with volume, it could squeeze toward 0.42 or higher — Summary: Every name has a micro float under 7.5M, real catalysts with SEC or PR confirmation, no active dilution or ATM, and strong volume with clean chart structures. If we see early volume and level reclaims, each one has the potential to move 20 -100%. Let's see how these plays out tomorrow 💪 — Key Levels BMGL: Targets 3.60 / 4.00 / 4.45 Stop 3.12 AEMD: Targets 1.41 / 1.50 / 1.65 Stop 1.17 ALUR: Targets 3.65 / 4.10 / 4.90 Stop 2.86 GLMD: Targets 2.35 / 2.49 / 2.77+ Stop 1.99 BENF: Targets 0.38 / 0.42 / 0.48 Stop 0.305
2 · Reply
quizzer
quizzer Jul. 10 at 12:16 AM
$AEMD Primed for a possible run tomorrow
0 · Reply
ATLDawg
ATLDawg Jul. 9 at 11:36 PM
0 · Reply
DougieFreshPicks
DougieFreshPicks Jul. 9 at 11:24 PM
$AEMD no problem 👍
0 · Reply
MGeronimo
MGeronimo Jul. 9 at 11:22 PM
$AEMD IN AT 1.34 5x NORMAL ON A LONG MOONSHOT PLAY
1 · Reply
dbr_island
dbr_island Jul. 9 at 11:09 PM
$NAK is paying 💰💰💰 $SUGP wants $2+ $HERZ wants $5+ at minimum $HUSA $AEMD lets get it
1 · Reply
FeliciaMath
FeliciaMath Jul. 9 at 10:53 PM
$AEMD sold at 1.8 today for 42% gain/$835. Very happy with that!
0 · Reply
TwongStocks
TwongStocks Jul. 9 at 10:43 PM
One month post-RS recap. $DUO did a 1:16 RS on Jun 9, closed $2.76. Hit an intraday high on $3.46 the day of the RS, but has traded below that since. Today closed $2.37 , down 14.13% from RS close. $AEMD 1:8 RS on Jun 9, closed $2.30 Intraday high of $2.88 the day of the RS. Like DUO, has traded below that since the RS, reaching a low of $1.11 on Jul 2. Today closed $1.45, down 36.96% from RS close. $NKTR 1:15 RS on Jun 9, closed $8.79. One of the few very successful stocks post-RS. On Jun 24, announced Ph2b trial results and the stock has climbed since then, reaching a high of $37.38 on Jun 25. Managed to stay above $20 even after a $115M dilution on July 1. Today closed $23.36, up 165.76% from RS close.
1 · Reply